What the New York City Marathon Can Teach Us About Equitable Access to Vaccines
What can the New York City Marathon teach those hoping to increase global vaccine equity? Quite a lot, it turns out.

What can the New York City Marathon teach those hoping to increase global vaccine equity? Quite a lot, it turns out.
The promise of COVID vaccines has been unevenly realized: fault lines have emerged between those able to secure doses and those left behind.
For COVID treatments and diagnostics to be broadly available at affordable prices, their IP must be considered a global public good.
Research funding contracts can help to safeguard against inequities in global allocation and distribution of lifesaving diagnostics, drugs, and vaccines.
Putting vaccine equity at the center of a pandemic treaty will already be a huge step towards global health’s decolonization.
The pandemic has laid bare the lack of regulation for the sharing of intellectual property needed for an effective and equitable response.
The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines.
Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.
An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.